0.17
0.17 (-8.99%)
As of Dec 16, 2022
Scopus Biopharma Inc. [SCPS]
Source:
Company Overview
Scopus Biopharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. our majority-owned subsidiary.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (212) 479-2513 |
| Industry | manufacturing |
| CEO | Joshua R. Lamstein |
| Website | scopusbiopharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | |
| Net Income | $-2.9 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -658.3% |
| Profit as % of Stockholder Equity | 27.9% |
Management Effectiveness
| Return on Equity | 27.9% |
| Return on Assets | -588.7% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $0.5 |
| Total Liabilities | $11 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
